[Tumour markers--case report].
Lamerz
R
R
Medizinische Klinik II, Klinikum Grosshadern, Ludwig-Maximilians-Universität München. Rolf.Lamerz@med.uni-muenchen.de
Stieber
P
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D014408:Biomarkers, Tumor; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011379:Prognosis; D012074:Remission Induction; D018239:Seminoma / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D013736:Testicular Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D013737:Testis / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D001761:Bleomycin; D005047:Etoposide; D003520:Cyclophosphamide; D002945:Cisplatin; D007069:Ifosfamide